Genentech, Inc.

F. Hoffmann-la Roche Ag

Brian Yaspan

Amy Dressen

Robert Royal Graham

Teodorica L Bugawan

Zhengrong Li

Erich Strauss

Tracy Staton

Joseph R Arron

Rajita Khosla

Vladimir Ramirez-Carrozzi

David Choy

The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.

Therapeutic and diagnostic methods for IL-33-mediated disorders

The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.

Compositions and method for treating complement-associated conditions

Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms

Growing community of inventors

Pacifica, CA, United States of America

Brian Yaspan